Gilead (NASDAQ: GILD) insider plans 29,215-share stock sale

Rhea-AI Filing Summary

Gilead Sciences insider Deborah Telman has filed a Form 144 notice to sell up to 29,215 shares of the company’s common stock on NASDAQ. The shares, with an aggregate market value of $3,771,948.65, are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The issuer reports 1,240,679,623 common shares outstanding.

The stock to be sold comes from a stock option exercise of 26,215 shares on 01/22/2026 paid in cash and 3,000 restricted stock units granted on 07/25/2023. The filing also lists prior Rule 10b5-1 sales for Deborah Telman over the past three months, including transactions on 11/12/2025, 12/15/2025, and 01/15/2026 with disclosed gross proceeds for each sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	29215	3771948.65	1240679623	01/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/22/2026	Exercise of Stock Options	Issuer			26215	01/22/2026	Cash
Common	07/25/2023	Restricted Stock Units	Issuer			3000	07/25/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DEBORAH TELMAN 333 Lakeside Drive Foster City CA 94404	Common	01/15/2026	1000	124310.00
10b5-1 Sales for DEBORAH TELMAN 333 Lakeside Drive Foster City CA 94404	Common	12/15/2025	1000	122000.00
10b5-1 Sales for DEBORAH TELMAN 333 Lakeside Drive Foster City CA 94404	Common	11/12/2025	53646	6590485.44

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Gilead (GILD) shares are covered by this Form 144 filing?

The Form 144 covers the proposed sale of 29,215 shares of Gilead common stock, with an indicated aggregate market value of $3,771,948.65.

How were the Gilead (GILD) shares in this Form 144 acquired?

The shares to be sold consist of 26,215 shares acquired on 01/22/2026 through an exercise of stock options for cash and 3,000 shares from restricted stock units dated 07/25/2023.

What recent Gilead (GILD) stock sales by Deborah Telman are disclosed?

The filing lists Rule 10b5-1 sales for Deborah Telman of Gilead common stock on 11/12/2025, 12/15/2025, and 01/15/2026, with individual transactions including 1,000-share sales and a larger sale of 53,646 shares, each showing related gross proceeds.

On which exchange are the Gilead (GILD) shares in this Form 144 expected to be sold?

The filing states that the Gilead common shares covered by the Form 144 are intended to be sold on the NASDAQ stock market.

Who is the broker for the Gilead (GILD) Form 144 share sale?

The planned sale of 29,215 Gilead common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY 10004.

What does the Form 144 representation about material information state for this Gilead (GILD) sale?

The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.